HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahata, S. K. Articles by O'Connor, D. T. Search for Related Content PubMed PubMed Citation Articles by Mahata, S. K. Articles by O'Connor, D. T. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 5, 2920-2928, January 29, 1999

Desensitization of Catecholamine Release
THE NOVEL CATECHOLAMINE RELEASE-INHIBITORY PEPTIDE CATESTATIN (CHROMOGRANIN A_344-364) ACTS AT THE RECEPTOR TO PREVENT NICOTINIC CHOLINERGIC TOLERANCE

From the Department of Medicine and Center for Molecular Genetics, University of California, and San Diego Veterans Administration Healthcare System, San Diego, California 92161

Nicotinic cholinergic receptors undergo desensitization upon repeated or prolonged exposure to agonist. We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment, catestatin (chromogranin A_344-364), on agonist-induced desensitization of catecholamine release from pheochromocytoma cells. In a dose-dependent fashion, the nicotinic antagonist catestatin blocked agonist desensitization of both catecholamine release (IC₅₀ ~ 0.24 µM) and ²²Na⁺ uptake (IC₅₀ ~ 0.31 µM), the initial step in nicotinic cationic signal transduction; both secretion inhibition and blockade of desensitization were noncompetitive with agonist. Desensitizing effects of the nicotinic agonists nicotine and epibatidine were blocked. This antagonist action was specific to desensitization by nicotinic agonists, since catestatin did not block desensitization of catecholamine release induced by agents which bypass the nicotinic receptor. Hill plots with slopes near unity suggested noncooperativity for catestatin effects on both nicotinic responses (secretory antagonism and blockade of desensitization). Human, bovine, and rat catestatins (as well as substance P) had similar potencies. IC₅₀ values for secretion inhibition and blockade of desensitization paralleled each other (r = 0.76, n = 10 antagonists, p = 0.01) for several noncompetitive nicotinic antagonists. Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitors of both secretion (p = 0.019) and desensitization (p = 0.005) than nonpeptide antagonists (trimethaphan, hexamethonium, procaine, phencyclidine, cocaine, or clonidine), and the peptides displayed enhanced selectivity to block desensitization versus secretion (p = 0.003). We conclude that catestatin is a highly potent, dose-dependent, noncompetitive, noncooperative, specific inhibitor of nicotinic desensitization, an effect which may have implications for control of catecholamine release.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				Y. Chen, F. Rao, J. L. Rodriguez-Flores, M. Mahata, M. M. Fung, M. Stridsberg, S. M. Vaingankar, G. Wen, R. M. Salem, M. Das, et al. Naturally Occurring Human Genetic Variation in the 3'-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1468 - 1481. [Abstract] [Full Text] [PDF]

				S. V. Kabadi and A. Ally Negative Cardiotropism by Catestatin and Its Variants Endocrinology, October 1, 2008; 149(10): 4778 - 4779. [Full Text] [PDF]

				R. Mazza, A. Gattuso, C. Mannarino, B. K. Brar, S. F. Barbieri, B. Tota, and S. K. Mahata Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H113 - H122. [Abstract] [Full Text] [PDF]

				N. Biswas, S. M. Vaingankar, M. Mahata, M. Das, J. R. Gayen, L. Taupenot, J. W. Torpey, D. T. O'Connor, and S. K. Mahata Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential Processing at Catestatin Region by Plasmin Endocrinology, February 1, 2008; 149(2): 749 - 757. [Abstract] [Full Text] [PDF]

				S.-R. Hwang, C. Garza, C. Mosier, T. Toneff, E. Wunderlich, P. Goldsmith, and V. Hook Cathepsin L Expression Is Directed to Secretory Vesicles for Enkephalin Neuropeptide Biosynthesis and Secretion J. Biol. Chem., March 30, 2007; 282(13): 9556 - 9563. [Abstract] [Full Text] [PDF]

				T. A. Greenwood, F. Rao, M. Stridsberg, N. R. Mahapatra, M. Mahata, E. O. Lillie, S. K. Mahata, L. Taupenot, N. J. Schork, and D. T. O'Connor Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion Physiol Genomics, May 16, 2006; 25(3): 470 - 479. [Abstract] [Full Text] [PDF]

				S. K. Mahata, M. Mahata, G. Wen, W. B. Wong, N. R. Mahapatra, B. A. Hamilton, and D. T. O'Connor The Catecholamine Release-Inhibitory "Catestatin" Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses Mol. Pharmacol., November 1, 2004; 66(5): 1180 - 1191. [Abstract] [Full Text] [PDF]

				B. McNeill, C. J. Montpetit, and S. F. Perry Catecholamine secretion in trout chromaffin cells experiencing nicotinic receptor desensitization is maintained by non-cholinergic neurotransmission J. Exp. Biol., December 1, 2003; 206(23): 4247 - 4253. [Abstract] [Full Text] [PDF]

				S. K. Mahata, N. R. Mahapatra, M. Mahata, T. C. Wang, B. P. Kennedy, M. G. Ziegler, and D. T. O'Connor Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo: DEMONSTRATION BY A NOVEL TRANSGENIC PROMOTER/PHOTOPROTEIN REPORTER AND INHIBITION OF SECRETION AND TRANSCRIPTION BY THE CHROMOGRANIN A FRAGMENT CATESTATIN J. Biol. Chem., August 22, 2003; 278(34): 32058 - 32067. [Abstract] [Full Text] [PDF]

				L. Taupenot, K. L. Harper, and D. T. O'Connor The Chromogranin-Secretogranin Family N. Engl. J. Med., March 20, 2003; 348(12): 1134 - 1149. [Full Text] [PDF]

				K.C. Wollert and H. Drexler Chromogranin A in heart failure Eur. Heart J., June 2, 2002; 23(12): 926 - 927. [Full Text] [PDF]

				M. Mahata, N. R. Mahapatra, D. T. O'Connor, and S. K. Mahata Chromaffin Cell Catecholamine Secretion: Bisindolylmaleimide Compounds Exhibit Novel and Potent Antagonist Effects at the Nicotinic Cholinergic Receptor in Pheochromocytoma Cells Mol. Pharmacol., June 1, 2002; 61(6): 1340 - 1347. [Abstract] [Full Text] [PDF]

				C. J. Herrero, E. Ales, A. J. Pintado, M. G. Lopez, E. Garcia-Palomero, S. K. Mahata, D. T. O'Connor, A. G. Garcia, and C. Montiel Modulatory Mechanism of the Endogenous Peptide Catestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis J. Neurosci., January 15, 2002; 22(2): 377 - 388. [Abstract] [Full Text] [PDF]

				M. d'Herbomez, V. Gouze, D. Huglo, M. Nocaudie, F. Pattou, C. Proye, J.-L. Wemeau, and X. Marchandise Chromogranin A Assay and 131I-MIBG Scintigraphy for Diagnosis and Follow-Up of Pheochromocytoma J. Nucl. Med., July 1, 2001; 42(7): 993 - 997. [Abstract] [Full Text] [PDF]

				S. K. Mahata, M. Mahata, A. R. Wakade, and D. T. O’Connor Primary Structure and Function of the Catecholamine Release Inhibitory Peptide Catestatin (Chromogranin A344-364): Identification of Amino Acid Residues Crucial for Activity Mol. Endocrinol., October 1, 2000; 14(10): 1525 - 1535. [Abstract] [Full Text]

				C. V. Taylor, L. Taupenot, S. K. Mahata, M. Mahata, H. Wu, S. Yasothornsrikul, T. Toneff, C. Caporale, Q. Jiang, R. J. Parmer, et al. Formation of the Catecholamine Release-inhibitory Peptide Catestatin from Chromogranin A. DETERMINATION OF PROTEOLYTIC CLEAVAGE SITES IN HORMONE STORAGE GRANULES J. Biol. Chem., July 21, 2000; 275(30): 22905 - 22915. [Abstract] [Full Text] [PDF]